321 related articles for article (PubMed ID: 27633917)
1. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
Lerner MZ; Lerner BA; Patel AA; Blitzer A
Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
[TBL] [Abstract][Full Text] [Related]
2. Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience.
Tang CG; Novakovic D; Mor N; Blitzer A
Laryngoscope; 2016 Mar; 126(3):678-81. PubMed ID: 26308153
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
Kang MS; Lee SJ; Choi HS; Lim JY
Clin Otolaryngol; 2021 Mar; 46(2):436-444. PubMed ID: 33260261
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.
Patel PN; Kabagambe EK; Starkweather JC; Keller M; Gamsarian V; Lee J; Kulkarni V; Garrett CG; Francis DO
JAMA Otolaryngol Head Neck Surg; 2018 Apr; 144(4):293-299. PubMed ID: 29423509
[TBL] [Abstract][Full Text] [Related]
5. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort.
Dharia I; Bielamowicz S
Laryngoscope; 2020 Nov; 130(11):2659-2662. PubMed ID: 31837152
[TBL] [Abstract][Full Text] [Related]
6. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
7. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
Blitzer A; Brin MF; Stewart CF
Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
[TBL] [Abstract][Full Text] [Related]
9. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
10. Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
Bradley JP; Barrow EM; Hapner ER; Klein AM; Johns MM
J Voice; 2017 May; 31(3):363-365. PubMed ID: 27839987
[TBL] [Abstract][Full Text] [Related]
11. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
[TBL] [Abstract][Full Text] [Related]
12. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
13. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
van Esch BF; Wegner I; Stegeman I; Grolman W
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
16. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
Nerurkar NK; Banu TP
J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
[TBL] [Abstract][Full Text] [Related]
17. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
French G; Bosch JD; Randall DR
J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
[TBL] [Abstract][Full Text] [Related]
18. Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
Lee SJ; Kang MS; Choi HS; Lim JY
Otolaryngol Head Neck Surg; 2021 Apr; 164(4):815-820. PubMed ID: 32957836
[TBL] [Abstract][Full Text] [Related]
19. Abductor paralysis after botox injection for adductor spasmodic dysphonia.
Venkatesan NN; Johns MM; Hapner ER; DelGaudio JM
Laryngoscope; 2010 Jun; 120(6):1177-80. PubMed ID: 20513036
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
Blitzer A
Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]